21 April 2023 : Original article
Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation
Chih-Hsien Cheng1ABCDE*, Hao-Chien Hung1BC, Jin-Chiao Lee1BC, Yu-Chao Wang1CD, Tsung-Han Wu1CD, Chen-Fang Lee1ABC, Ting-Jung Wu1BC, Hong-Shiue Chou1BC, Kun-Ming Chan
1BC, Wei-Chen Lee1ABCD
DOI: 10.12659/AOT.938731
Ann Transplant 2023; 28:e938731
Table 2 Patients with HBV recurrence.
| Patient | Time to recurrence (years) | Post-transplant antiviral therapy | Antiviral therapy after HBV recurrence | HBV DNA at recurrence (IU/ml) | YIDD mutation | HBsAg decline | HBsAg prezent (IU/ml) | HBV DNA AT prezent (IUI/ml) | CKD stage before TDF | CKD stage before TAF |
|---|---|---|---|---|---|---|---|---|---|---|
| 5 | 6 | LAM+ADV | LAM+TDF | Undetec-table | No | <1 log at 48 w with TDF | Undetec-table | Undetec-table | 2 | 2 |
| 6 | 2 | ETV | ETV+TDF | 59.6×10 | No | <1 log at 72 w with TDF | Undetec-table | Undetec-table | 3a | 4 |
| 9 | 12 | LAM+ADV | LAM+TDF | 1.7×10 | Yesseq 552 | No | 48 | Undetec-table | 2 | 2 |
| 12 | 15 | LAM | TDF | 68.3×10 | No | <1 log at 48 w with TDF | – | Undetec-table | 2 | 2 |
| 15 | 6 | LAM+ADV | TDF | 2115 | Yesseq 552 | <1 log at 48 w with TDF | 56 | Undetec-table | 1 | 1 |
| 16 | 2 | ETV+ADV | ETV+TDF | Undetec-table | No | No | 142 | Undetec-table | 1 | 1 |
| HBV – hepatitis B virus; LAM – lamivudine; ADV – adefovir; ETV – entecavir; TBV – telbivudine; TDF – tenofovir disoproxil fumarate; TAF – tenofovir alafenamide; CKD – chronic kidney disease; Seq – sequence. | ||||||||||